title: Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
abstract: AIDS-related aggressive B cell lymphoma (HIV-NHL) is the second most common HIV-associated malignancy. In contrast, Hodgkin-lymphoma (HL) is one of the most common non-AIDS-defining malignancies. Current evidence-based recommendations for the treatment of HIV-associated lymphoma (HIV-lymphoma) are not available. A panel of experts in the field of HIV-related lymphoma performed literature searches of the PubMed, Medline, and Cochrane databases. The consensus process was carried out as an e-mail and meeting-based discussion group. Six cycles of R-CHOP or R-EPOCH are standard of care for patients (pts) with diffuse large B cell lymphoma (DLBCL). Pts with Burkitt lymphoma and good performance status should receive dose-intensive regimens such as the GMALL B-ALL/NHL protocol. Standard therapy has not been defined for pts with plasmablastic and primary effusion lymphoma. Pts with lymphoma in sensitive relapse should receive high-dose chemotherapy followed by autologous stem cell transplantation. Stage- and risk adapted treatment yields high remission and survival rates in pts with HIV-HL similar to those achieved in HIV-negative HL pts. Combination antiretroviral therapy (cART) should be applied concurrently to chemotherapy provided that pharmacokinetic interactions are being considered. Pts with HIV-lymphoma should usually be treated in an identical manner to HIV-negative patients.
authors.affiliation: Department of Hematology, Oncology and Palliative Care, Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Sanatoriumsplatz 2, 81545, Munich, Germany, marcus.hentrich@klinikum-muenchen.de.
authors.forename: Marcus
authors.initials: M
authors.lastname: Hentrich
authors.forename: Christian
authors.initials: C
authors.lastname: Hoffmann
authors.forename: Franz
authors.initials: F
authors.lastname: Mosthaf
authors.forename: Markus
authors.initials: M
authors.lastname: Müller
authors.forename: Jan
authors.initials: J
authors.lastname: Siehl
authors.forename: Christoph
authors.initials: C
authors.lastname: Wyen
authors.forename: Manfred
authors.initials: M
authors.lastname: Hensel
mesh_terms: D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D005871:Castleman Disease / Q000150:complications / Q000188:drug therapy; D016543:Central Nervous System Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004347:Drug Interactions; D005047:Etoposide / Q000008:administration & dosage; D015658:HIV Infections / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D019380:Anti-HIV Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone; D008727:Methotrexate